Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download

Globant shares jump 13% as AI-driven growth boosts Q1 revenue and share buyback plans.

Company Fundamentals
15 May 2026
Lekha Gupta
View Source
Bullish
pluang ai news

Globant reported Q1 adjusted EPS of $1.50, matching expectations, and revenue of $607.1 million, slightly above estimates. The company's AI Pods contributed significantly to growth, with annual recurring revenue reaching $32.8 million. Despite a slight decline in margins, Globant generated $36.1 million in free cash flow and repurchased $50 million in shares, announcing a new $125 million buyback plan. The company reaffirmed its FY26 guidance with a modest revenue range adjustment and expects continued growth driven by AI services. Several analysts lowered price targets, but shares rose 13% following the earnings release.

More News

New Nasdaq rules could trigger $60B+ in SpaceX ETF buying right after IPO listing.

New Nasdaq rules could trigger $60B+ in SpaceX ETF buying right after IPO listing.

Former Goldman Sachs exec Chan Ahn highlights that Nasdaq's updated index-inclusion rules may lead to over $60 billion in institutional ETF buying of SpaceX shares soon after its IPO. This is due to a 'fast entry' rule allowing SpaceX to join the Nas...

Market News
Bullish
26 minutes ago
Investigation launched into Alphatec Holdings over possible securities law violations after Q1 earnings miss.

Investigation launched into Alphatec Holdings over possible securities law violations after Q1 earnings miss.

Glancy Prongay Wolke & Rotter LLP has started a securities fraud investigation into Alphatec Holdings following the company's Q1 2026 earnings report, which missed revenue estimates and lowered its full-year outlook. Alphatec reported lower deliverie...

Market News
Bearish
1 hour ago
Cancer centers rush to enroll patients in Revolution Medicines' pancreatic cancer drug after positive trial results.

Cancer centers rush to enroll patients in Revolution Medicines' pancreatic cancer drug after positive trial results.

Revolution Medicines received FDA approval for an expanded access program for its pancreatic cancer drug, daraxonrasib, following positive Phase 3 trial results showing significant survival benefits. The drug demonstrated a median overall survival of...

Market News
Bullish
1 hour ago
SaintQuant launches AI crypto trading bots amid Bitcoin surge and rising institutional interest

SaintQuant launches AI crypto trading bots amid Bitcoin surge and rising institutional interest

SaintQuant has officially launched its AI-driven quantitative crypto trading platform, offering retail investors easy, no-code access to automated trading strategies. This launch coincides with Bitcoin surpassing $82,000 and record institutional infl...

Market News
Bullish
2 hours ago
SpaceX IPO prospectus may drop next week, targeting $70-75B raise and $1.75T valuation, with heavy retail investor focus.

SpaceX IPO prospectus may drop next week, targeting $70-75B raise and $1.75T valuation, with heavy retail investor focus.

SpaceX is expected to release its IPO prospectus soon, aiming to raise $70-75 billion and seek a valuation around $1.75 trillion, which would make it one of the most valuable public companies globally. The company's revenue is largely driven by Starl...

Market News
Neutral
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App